213 related articles for article (PubMed ID: 6090838)
41. 5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation.
Cusack NJ; Hourani SM
Br J Pharmacol; 1981 Mar; 72(3):443-7. PubMed ID: 7260485
[TBL] [Abstract][Full Text] [Related]
42. The platelet strip. I. A low-fibrin contractile model of thrombin-activated platelets.
Salganicoff L; Loughnane MH; Sevy RW; Russo M
Am J Physiol; 1985 Sep; 249(3 Pt 1):C279-87. PubMed ID: 3898863
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of human platelet aggregation by parathyroid hormone. Is cyclic AMP implicated?
Benigni A; Livio M; Dodesini P; Schieppati A; Panigada M; Mecca G; de Gaetano G; Remuzzi G
Am J Nephrol; 1985; 5(4):243-7. PubMed ID: 2996352
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives.
Harris DN; Asaad MM; Phillips MB; Goldenberg HJ; Antonaccio MJ
J Cyclic Nucleotide Res; 1979; 5(2):125-34. PubMed ID: 221552
[TBL] [Abstract][Full Text] [Related]
45. Effect of OP 1206, a prostaglandin E1 derivative, on guinea-pig platelet functions.
Tsuboi T; Fujitani B; Maeda J; Yoshida K; Shimizu M; Kawasaki A; Okegawa T; Tsuboshima M
Thromb Res; 1980 Dec 1-15; 20(5-6):573-80. PubMed ID: 7233385
[No Abstract] [Full Text] [Related]
46. Prostaglandin E1 inhibitis platelet aggregation by a pathway independent of adenosine 3',5'-monophosphate.
Sinha AK; Colman RW
Science; 1978 Apr; 200(4338):202-3. PubMed ID: 204997
[TBL] [Abstract][Full Text] [Related]
47. In vitro effect of a thymic epithelial culture supernate or thymosin fraction 5 on rabbit platelet aggregation and intracellular cyclic AMP levels.
Hashimoto S; Itoh Y; Kawaguchi A; Mizuno Y; Muraoka M; Tsuchiya M
J Cell Physiol; 1987 Dec; 133(3):499-506. PubMed ID: 2826498
[TBL] [Abstract][Full Text] [Related]
48. The effects of thrombin on adenyl cyclase activity and a membrane protein from human platelets.
Brodie GN; Baenziger NL; Chase LR; Majerus PW
J Clin Invest; 1972 Jan; 51(1):81-8. PubMed ID: 4331802
[TBL] [Abstract][Full Text] [Related]
49. Investigation of possible mechanisms of pyridoxal 5'-phosphate inhibition of platelet reactions.
Lam SC; Harfenist EJ; Packham MA; Mustard JF
Thromb Res; 1980 Dec 1-15; 20(5-6):633-45. PubMed ID: 6262940
[No Abstract] [Full Text] [Related]
50. Dissociation of the aggregating effect and the inhibitory effect upon cyclic adenosine monophosphate accumulation by adrenaline and adenosine diphosphate in human platelets.
Stormorken H; Lyberg T; Hakvaag L; Nakstad B
Thromb Res; 1987 Feb; 45(4):363-70. PubMed ID: 3033838
[TBL] [Abstract][Full Text] [Related]
51. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP.
Bushfield M; McNicol A; MacIntyre DE
Biochem J; 1985 Nov; 232(1):267-71. PubMed ID: 3002327
[TBL] [Abstract][Full Text] [Related]
53. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
54. Platelet prostaglandin E1 hyposensitivity in schizophrenia: decrease in cyclic AMP formation and in inhibitory effects on aggregation.
Kaiya H; Ofuji M; Nozaki M; Tsurumi K
Psychopharmacol Bull; 1990; 26(3):381-4. PubMed ID: 2177206
[TBL] [Abstract][Full Text] [Related]
55. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
56. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
57. Regulatory role of cyclic adenosine 3',5'-monophosphate on the platelet cyclooxygenase and platelet function.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1979 Jan; 582(1):44-58. PubMed ID: 216415
[TBL] [Abstract][Full Text] [Related]
58. Cyclic 3',5'-adenosine monophosphate in human blood platelets. II. Effect of N6-2'-o-dibutyryl cyclic 3',5'-adenosine monophosphate on platelet function.
Salzman EW; Levine L
J Clin Invest; 1971 Jan; 50(1):131-41. PubMed ID: 4322665
[TBL] [Abstract][Full Text] [Related]
59. Human platelet aggregation and cAMP system--cAMP level, adenyl cyclase, phosphodiesterase.
Wang TY; Hussey CV; Sasse EA; Fobian JE
Ann Clin Lab Sci; 1978; 8(5):403-12. PubMed ID: 213009
[TBL] [Abstract][Full Text] [Related]
60. Effects of protopine on blood platelet aggregation. II. Effect on metabolic system of adenosine 3',5'-cyclic monophosphate in platelets.
Shiomoto H; Matsuda H; Kubo M
Chem Pharm Bull (Tokyo); 1990 Aug; 38(8):2320-2. PubMed ID: 2177684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
